Co-Pilot was a 3 drug combo and the Enanta PR said about it:
Isn't ritonavir considered a drug? I realize it's not an HCV DAA but, point being, it's another component to HCV therapy and so why use four components when there could well be three, if not even just two, that are effective in future HCV therapy?
Market Data 
Markets 
